TANK‐binding kinase 1 is a mediator of platelet‐induced EMT in mammary carcinoma cells

Zhang, Yanyu; Unnithan, Ragaseema Valsala Madhavan; Hamidi, Anahita; Caja, Laia; Saupe, Falk; Moustakas, Aristidis; Cedervall, Jessica; Olsson, Anna‐Karin

doi:10.1096/fj.201801936rrr

Cited by 25 publications

(26 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition to ovarian cancer and glioblastoma, Guo et al24 reported that the expression of IKBKE was increased in 98 cases of NSCLC, and the sensitivity of NSCLC cell lines to chemotherapy drugs was increased after silencing IKBKE, suggesting that IKBKE plays a key role in lung cancer and tumor resistance. Zhang et al44 also demonstrated that TBK1 contributes to tumor invasion and might be a driving factor for metastatic spread of breast cancer. Thus, IKBKE/TBK1 dual inhibitors combined with adjuvant chemotherapy may be a potential strategy for high-risk stage I NSCLC patients.…”

Section: Discussionmentioning

confidence: 97%

<p>Expression and prognostic role of IKBKE and TBK1 in stage I non-small cell lung cancer</p>

Wang¹,

Teng²,

Lü³

et al. 2019

CMAR

View full text Add to dashboard Cite

Background The inhibitors of nuclear factor kappa-B kinase subunit epsilon ( IKBKE ) and TANK-binding kinase 1 ( TBK1 ) are important members of the nonclassical IKK family that share the kinase domain. They are important oncogenes for activation of several signaling pathways in several tumors. This study aims to explore the expression of IKBKE and TBK1 and their prognostic role in stage I non-small cell lung cancer (NSCLC). Patients and methods A total of 142 surgically resected stage I NSCLC patients were enrolled and immunohistochemistry of IKBKE and TBK1 was performed. Results IKBKE and TBK1 were expressed in 121 (85.2%) and 114 (80.3%) of stage I NSCLC patients respectively. IKBKE expression was significantly associated with TBK1 expression ( P =0.004). Furthermore, multivariate regression analyses showed there was a significant relationship between patients with risk factors, the recurrence pattern of metastasis and IKBKE+/TBK1+ co-expression ( P =0.032 and P =0.022, respectively). In Kaplan–Meier survival curve analyses, the IKBKE+/TBK1+ co-expression subgroup was significantly associated with poor overall survival ( P =0.014). Conclusions This is the first study to investigate the relationship between IKBKE and TBK1 expression and clinicopathologic characteristics in stage I NSCLC patients. IKBKE+/TBK1+ co-expression was significantly obvious in patients with risk factors and with recurrence pattern of distant metastasis. Furthermore, IKBKE+/TBK1+ is also an effective prognostic predictor for poor overall survival.

show abstract

Section: Discussionmentioning

confidence: 97%

<p>Expression and prognostic role of IKBKE and TBK1 in stage I non-small cell lung cancer</p>

Wang¹,

Teng²,

Lü³

et al. 2019

CMAR

View full text Add to dashboard Cite

show abstract

“…Zhang и соавт. установили роль белка TBK1 (TANK-связывающей киназы 1) в качестве медиатора тромбоцит-индуцированного ЭМП [70]. Будучи киназой, способной фосфорилировать NF-кB, в здоровой ткани этот белок играет роль в регуляции клеточной пролиферации и апоптоза [71].…”

Section: тромбоциты способствуют эпителиально-мезенхимальному переходу и метастазированию опухолевых клетокunclassified

“…показали, что инкубация клеток рака молочной железы линий Ep5 и MCF10A с тромбоцитами приводит к запуску ЭМП в опухолевых клетках путем активации TBK1 и p56 (транскрипционного фактора семейства NF-кB). Инактивация TBK1 с помощью малой интерферирующей РНК в значительной степени тормозит тромбоцит-индуцированный ЭМП и активацию p56 в обеих клеточных линиях [70].…”

Analysis of platelet RNA: a non-invasive method for studying the expression of tumor genes

Tesakov

Мартьянов

Druy

et al. 2021

Voprosy gematologii/onkologii i immunopatologii v pediatrii

View full text Add to dashboard Cite

Nowadays much attention is paid to non-invasive methods of cancer diagnostics and monitoring. One of the promising methods is the sequencing of platelet RNA (tumor-educated platelets), in which, as it was previously established, the mRNA repertoire changes in various oncological diseases. Thus, platelets can contain information about the molecular genetic characteristics of tumor. This review summarizes the current understanding of the mechanisms of interaction between tumor cells and platelets, and also discusses the possibilities of using platelet transcriptome analysis methods for diagnosing and assessing the dynamics of the tumor state, in particular, in response to therapy, as well as the current limitations for a wide range of introduction of this method into clinical practice.

show abstract

“…Neutrophils can release neutrophil extracellular traps (NETs) that can promote metastases when they are in contact with CTCs [ 41 , 42 ]. Platelets can also interact with cancer cells to acquire invasive mesenchymal-like phenotype either by direct or indirect interactions through TGFβ and Wnt-β-catenin pathways [ 43 , 44 , 45 ].…”

Section: Immune Cells and Metastasismentioning

confidence: 99%

Immunotherapies and Metastatic Cancers: Understanding Utility and Predictivity of Human Immune Cell Engrafted Mice in Preclinical Drug Development

Kähkönen¹,

Halleen²,

Bernoulli

2020

Cancers

View full text Add to dashboard Cite

Metastases cause high mortality in several cancers and immunotherapies are expected to be effective in the prevention and treatment of metastatic disease. However, only a minority of patients benefit from immunotherapies. This creates a need for novel therapies that are efficacious regardless of the cancer types and metastatic environments they are growing in. Preclinical immuno-oncology models for studying metastases have long been limited to syngeneic or carcinogenesis-inducible models that have murine cancer and immune cells. However, the translational power of these models has been questioned. Interactions between tumor and immune cells are often species-specific and regulated by different cytokines in mice and humans. For increased translational power, mice engrafted with functional parts of human immune system have been developed. These humanized mice are utilized to advance understanding the role of immune cells in the metastatic process, but increasingly also to study the efficacy and safety of novel immunotherapies. From these aspects, this review will discuss the role of immune cells in the metastatic process and the utility of humanized mouse models in immuno-oncology research for metastatic cancers, covering several models from the perspective of efficacy and safety of immunotherapies.

show abstract

TANK‐binding kinase 1 is a mediator of platelet‐induced EMT in mammary carcinoma cells

Cited by 25 publications

References 42 publications

<p>Expression and prognostic role of IKBKE and TBK1 in stage I non-small cell lung cancer</p>

<p>Expression and prognostic role of IKBKE and TBK1 in stage I non-small cell lung cancer</p>

Analysis of platelet RNA: a non-invasive method for studying the expression of tumor genes

Immunotherapies and Metastatic Cancers: Understanding Utility and Predictivity of Human Immune Cell Engrafted Mice in Preclinical Drug Development

Contact Info

Product

Resources

About